Can valproic acid (Depakote) be taken together with levetiracetam (Keppra)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Can You Take Both Depakote and Keppra Together?

Yes, valproic acid (Depakote) and levetiracetam (Keppra) can be safely taken together—there are no clinically significant pharmacokinetic interactions between these medications, and combination therapy is commonly used in clinical practice for seizure management. 1

Evidence for Safety of Combination Therapy

No Pharmacokinetic Interactions

  • FDA labeling for Keppra explicitly states that valproate (500 mg twice daily) does not modify the rate or extent of levetiracetam absorption, plasma clearance, or urinary excretion. 1

  • Levetiracetam (1500 mg twice daily) does not alter the pharmacokinetics of valproate in healthy volunteers. 1

  • Neither drug affects the plasma concentration of the other when used together, as demonstrated in placebo-controlled clinical studies. 1

  • In vitro studies confirm that levetiracetam does not affect the glucuronidation of valproic acid, the primary metabolic pathway for valproate. 1

  • A dedicated pharmacokinetic study in 16 healthy volunteers found no significant differences in drug exposure (AUC) when levetiracetam was administered alone versus with steady-state valproic acid. 2

Clinical Use in Guidelines

  • Emergency medicine guidelines recommend both valproate and levetiracetam as Level B or Level C options for refractory status epilepticus, indicating they may be used sequentially or in combination when benzodiazepines fail. 3

  • Status epilepticus management guidelines from 2024 list both valproic acid and levetiracetam among acceptable second-line agents, with no contraindication to their combined use. 4

  • Brain tumor seizure management guidelines (NCCN) identify both valproic acid and levetiracetam as preferred antiepileptic options, with no restriction against combination therapy. 5, 6

Evidence for Efficacy of Combination Therapy

  • A 2022 meta-analysis of 7 randomized controlled trials (617 pediatric patients) found that sodium valproate combined with levetiracetam significantly improved overall therapeutic effect compared to valproate alone (RR=1.24,95% CI: 1.16-1.33). 7

  • The same meta-analysis demonstrated that combination therapy significantly reduced adverse drug reactions compared to monotherapy (RR=0.54,95% CI: 0.37-0.79). 7

  • Combination therapy is used successfully in intensive care settings for high-risk seizure patients, including those with subarachnoid hemorrhage. 8

Important Clinical Considerations

When Combination Therapy Is Appropriate

  • Refractory epilepsy where monotherapy has failed to achieve adequate seizure control 3, 7

  • Status epilepticus that has not responded to first-line benzodiazepines 3, 4

  • Patients requiring enhanced seizure control in high-risk situations (e.g., brain tumors, neurosurgical patients) 5, 8

Monitoring Requirements

  • Although no dose adjustment is required when combining these medications, monitor for additive central nervous system effects such as somnolence and dizziness. 1

  • Valproic acid levels should be monitored if the antibiotic meropenem is added, as this combination can significantly reduce valproate plasma concentrations. 8

  • Both medications can cause hematologic abnormalities and liver function test changes, so baseline and periodic monitoring is appropriate. 1

Special Populations

  • In women of childbearing potential, valproic acid carries well-documented teratogenic risks and should be avoided if possible; levetiracetam is relatively safer but has been associated with specific congenital anomalies (hypospadias). 9

  • Withdrawal of valproic acid during pregnancy increases the odds of tonic-clonic seizure recurrence (OR 1.73,95% CI 1.06-2.84), so the decision to continue or discontinue must weigh seizure risk against teratogenic risk. 10

  • In pediatric patients, both medications may increase ADHD symptoms and anger features, with levetiracetam showing a statistically significant increase in patients meeting diagnostic criteria for ADHD+ODD (16% pre-treatment to 48% post-treatment). 11

Drug Interactions to Avoid

  • Enzyme-inducing antiepileptics (phenytoin, carbamazepine, phenobarbital) should be avoided when possible due to extensive drug interactions, but they do not preclude the use of valproate-levetiracetam combination. 5, 6, 1

  • The antibiotic meropenem significantly reduces valproic acid plasma concentrations and should be avoided or used with close monitoring. 8

Practical Prescribing Algorithm

For patients requiring dual therapy:

  1. Start with standard dosing of each medication based on indication (seizure type, patient weight, renal function) 1

  2. No dose adjustment is needed solely because the medications are combined 1, 2

  3. Monitor for additive CNS side effects (somnolence, dizziness) and adjust doses if tolerability issues arise 1

  4. Obtain baseline and periodic liver function tests and complete blood counts 1

  5. In women of childbearing potential, strongly consider alternatives to valproic acid or ensure highly effective contraception 9, 10

  6. In pediatric patients, monitor for behavioral changes including increased irritability, hyperactivity, and oppositional behaviors 11

References

5
Guideline

Discontinuation and Management of Levetiracetam in Brain Tumor Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

6
Guideline

Alternative Antiepileptic Options for Seizure Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

Can Keppra (levetiracetam) and Depakote (valproic acid) be used together, and what are the recommended dosing and monitoring guidelines?
Can I safely combine levetiracetam (Keppra) 1 g twice daily with valproic acid (Depakote) 250 mg every 8 hours in a patient with mildly elevated liver enzymes (AST 59 U/L, ALT 68 U/L), and what concise recommendations and alternative mood‑stabilizing medications are appropriate for behavioral control?
Does levofloxacin (Levaquin) interact with valproic acid and levetiracetam (Keppra)?
Can amitriptyline be combined with levetiracetam (Keppra) and valproic acid (Depakote)?
Can I initiate divalproex (valproate) for mood stabilization in a patient with seizures who is currently taking levetiracetam (Keppra) 750 mg twice daily?
What is the best management for a 34‑week pregnant woman with abdominal pain and a history of two prior lower‑segment cesarean sections?
What does the whirl sign on imaging indicate and what is the recommended management for patients with acute abdominal pain who demonstrate this finding?
Why can gluten ingestion cause periorbital edema?
What is the normal serum testosterone range for a transgender female receiving testosterone injections?
What is the elimination half‑life of Strattera (atomoxetine) in adults?
What does an arterial blood gas with pH 7.52, PaCO₂ 31 mm Hg, PaO₂ 70 mm Hg, HCO₃⁻ 25 mmol/L, base excess +2.8 and SpO₂ 95.3% indicate?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.